Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $797.82 million. The enterprise value is $774.52 million.
Important Dates
The next estimated earnings date is Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 120.97 million shares outstanding. The number of shares has increased by 27.20% in one year.
| Current Share Class | 120.97M |
| Shares Outstanding | 120.97M |
| Shares Change (YoY) | +27.20% |
| Shares Change (QoQ) | +4.01% |
| Owned by Insiders (%) | 4.02% |
| Owned by Institutions (%) | 42.28% |
| Float | 116.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.30 |
| Forward PS | 15.12 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.53
| Current Ratio | 3.53 |
| Quick Ratio | 3.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -31.12% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -74.57% |
| Revenue Per Employee | $310,789 |
| Profits Per Employee | -$458,042 |
| Employee Count | 142 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.28 |
Taxes
| Income Tax | -14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.77% in the last 52 weeks. The beta is 1.76, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 1.76 |
| 52-Week Price Change | +36.77% |
| 50-Day Moving Average | 4.76 |
| 200-Day Moving Average | 3.53 |
| Relative Strength Index (RSI) | 68.23 |
| Average Volume (20 Days) | 3,951,016 |
Short Selling Information
The latest short interest is 11.58 million, so 9.57% of the outstanding shares have been sold short.
| Short Interest | 11.58M |
| Short Previous Month | 8.88M |
| Short % of Shares Out | 9.57% |
| Short % of Float | 9.97% |
| Short Ratio (days to cover) | 3.72 |
Income Statement
In the last 12 months, AQST had revenue of $44.13 million and -$65.04 million in losses. Loss per share was -$0.69.
| Revenue | 44.13M |
| Gross Profit | 26.96M |
| Operating Income | -52.60M |
| Pretax Income | -65.06M |
| Net Income | -65.04M |
| EBITDA | -51.99M |
| EBIT | -52.60M |
| Loss Per Share | -$0.69 |
Full Income StatementBalance Sheet
The company has $60.54 million in cash and $40.26 million in debt, giving a net cash position of $20.28 million or $0.17 per share.
| Cash & Cash Equivalents | 60.54M |
| Total Debt | 40.26M |
| Net Cash | 20.28M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | -72.59M |
| Book Value Per Share | -0.73 |
| Working Capital | 58.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$49.68 million and capital expenditures -$337,000, giving a free cash flow of -$50.02 million.
| Operating Cash Flow | -49.68M |
| Capital Expenditures | -337,000 |
| Free Cash Flow | -50.02M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
Gross margin is 61.09%, with operating and profit margins of -119.19% and -147.38%.
| Gross Margin | 61.09% |
| Operating Margin | -119.19% |
| Pretax Margin | -147.41% |
| Profit Margin | -147.38% |
| EBITDA Margin | -117.81% |
| EBIT Margin | -119.19% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.20% |
| Shareholder Yield | -27.20% |
| Earnings Yield | -8.18% |
| FCF Yield | -6.29% |
Analyst Forecast
The average price target for AQST is $10.71, which is 62.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.71 |
| Price Target Difference | 62.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 33.23% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AQST has an Altman Z-Score of -5.39 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.39 |
| Piotroski F-Score | 1 |
